HomeCompareGENE vs O

GENE vs O: Dividend Comparison 2026

GENE yields 261.44% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GENE wins by $612.77M in total portfolio value
10 years
GENE
GENE
● Live price
261.44%
Share price
$0.77
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$612.80M
Annual income
$349,686,678.74
Full GENE calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — GENE vs O

📍 GENE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGENEO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GENE + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GENE pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GENE
Annual income on $10K today (after 15% tax)
$22,222.22/yr
After 10yr DRIP, annual income (after tax)
$297,233,676.93/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, GENE beats the other by $297,229,339.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GENE + O for your $10,000?

GENE: 50%O: 50%
100% O50/50100% GENE
Portfolio after 10yr
$306.42M
Annual income
$174,845,890.74/yr
Blended yield
57.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

GENE
No analyst data
Altman Z
-24.5
Piotroski
2/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GENE buys
0
O buys
0
No recent congressional trades found for GENE or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGENEO
Forward yield261.44%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$612.80M$34.2K
Annual income after 10y$349,686,678.74$5,102.74
Total dividends collected$585.16M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: GENE vs O ($10,000, DRIP)

YearGENE PortfolioGENE Income/yrO PortfolioO Income/yrGap
1← crossover$36,844$26,143.79$10,818$608.16+$26.0KGENE
2$129,445$90,022.09$11,787$741.68+$117.7KGENE
3$434,094$295,587.53$12,946$911.00+$421.1KGENE
4$1,390,885$926,404.44$14,345$1,127.94+$1.38MGENE
5$4,262,362$2,774,115.59$16,056$1,409.05+$4.25MGENE
6$12,505,839$7,945,111.88$18,171$1,777.83+$12.49MGENE
7$35,167,310$21,786,062.26$20,820$2,268.21+$35.15MGENE
8$94,885,057$57,256,035.19$24,188$2,929.90+$94.86MGENE
9$245,903,396$144,376,384.91$28,533$3,837.11+$245.87MGENE
10$612,803,313$349,686,678.74$34,235$5,102.74+$612.77MGENE

GENE vs O: Complete Analysis 2026

GENEStock

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Full GENE Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this GENE vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GENE vs SCHDGENE vs JEPIGENE vs KOGENE vs MAINGENE vs STAGGENE vs ADCGENE vs NNNGENE vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.